- Home
- OCS vs IGR Comparison
OCS vs IGR Comparison
Compare OCS & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OCS | IGR |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.4M | 693.0M |
| IPO Year | 2022 | 2003 |
Fundamental Metrics
Financial Performance| Metric | OCS | IGR |
|---|---|---|
| Price | $10.07 | $12.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $42.00 | N/A |
| AVG Volume (30 Days) | 142.9K | ★ 486.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $466.06 | N/A |
| Revenue Next Year | $479.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.50 | $4.15 |
| 52 Week High | $34.48 | $13.67 |
Technical Indicators
Market Signals| Indicator | OCS | IGR |
|---|---|---|
| Relative Strength Index (RSI) | 24.29 | 87.47 |
| Support Level | N/A | $4.50 |
| Resistance Level | $13.49 | N/A |
| Average True Range (ATR) | 0.53 | 0.16 |
| MACD | -0.21 | 0.94 |
| Stochastic Oscillator | 3.42 | 88.42 |
Price Performance
Historical ComparisonAbout OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.